Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcus Biosciences (RCUS) Cash from Investing Activities (2017 - 2025)

Historic Cash from Investing Activities for Arcus Biosciences (RCUS) over the last 9 years, with Q3 2025 value amounting to $79.0 million.

  • Arcus Biosciences' Cash from Investing Activities rose 37241.38% to $79.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $299.0 million, marking a year-over-year increase of 37943.93%. This contributed to the annual value of -$84.0 million for FY2024, which is 14329.9% down from last year.
  • Per Arcus Biosciences' latest filing, its Cash from Investing Activities stood at $79.0 million for Q3 2025, which was up 37241.38% from $137.0 million recorded in Q2 2025.
  • Arcus Biosciences' 5-year Cash from Investing Activities high stood at $137.0 million for Q2 2025, and its period low was -$268.0 million during Q1 2022.
  • For the 5-year period, Arcus Biosciences' Cash from Investing Activities averaged around -$3.1 million, with its median value being $26.0 million (2023).
  • In the last 5 years, Arcus Biosciences' Cash from Investing Activities skyrocketed by 1371029.41% in 2021 and then plummeted by 725950.72% in 2022.
  • Arcus Biosciences' Cash from Investing Activities (Quarter) stood at $18.8 million in 2021, then skyrocketed by 150.24% to $47.0 million in 2022, then crashed by 40.43% to $28.0 million in 2023, then skyrocketed by 82.14% to $51.0 million in 2024, then surged by 54.9% to $79.0 million in 2025.
  • Its last three reported values are $79.0 million in Q3 2025, $137.0 million for Q2 2025, and $32.0 million during Q1 2025.